Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma

Complete title: A Multi-center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma

Research Study Number 20152183
Principal Investigator John Thompson, MD
Phase II

Research Study Description

The purpose of this study is to evaluate the progression free survival (PFS), based on investigator radiologic review, of AGS-16C3F compared to axitinib in subjects with metastatic renal cell carcinoma.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number 20152183
Contact Seattle Cancer Care Alliance Intake Office
Telephone 800-804-8824 / 206-606-1024

Keywords: Kidney Cancer; Renal Cancer; Solid Tumors; Urogenital Neoplasms; Neoplasms, Glandular and Epithelial; Adenocarcinoma; Carcinoma

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials